Clinical Trial

Breast Cancer Implementation Science Study With Educational Intervention

Recruiting
View on ClinicalTrials.gov →
Summary
A study uniquely focused on system-based practice change, measuring the impact of educational interventions on both patients and clinicians for the recognition and management of treatment-related adverse effects for HER2+/HER2 low breast cancer patients on or about to start on HER2 targeted antibody drug conjugates (fam-trastuzumab deruxtecan-nxki or ado-trastuzumab emtansine) and shared decision-making methodologies to improve adverse event (AE) management and patient-clinician communications.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-04-04.
Status change: Not Yet Recruiting → Recruiting 2026-03-24
Trial Details
NCT Number NCT06927895
Lead Sponsor NYU Langone Health
Collaborators: Daiichi Sankyo, Kaplan North America
Conditions Breast Cancer
Enrollment 30 participants
Start Date 2025-07-03
Primary Completion 2027-08-31 (estimated)
Study Completion 2027-08-31 (estimated)
Updated on ClinicalTrials.gov 2026-03-30